Susan Wan

Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I)

John Northover, Rob Glynne‐Jones, David Sebag‐Montefiore et al. · British Journal of Cancer · 2010 · 422 citations · Full text

The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity

Fiona Thistlethwaite, David E. Gilham, Ryan D. Guest et al. · Cancer Immunology Immunotherapy · 2017 · 395 citations · Full text

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9

EXTRA—A Multicenter Phase II Study of Chemoradiation Using a 5 Day per Week Oral Regimen of Capecitabine and Intravenous Mitomycin C in Anal Cancer

Rob Glynne‐Jones, Helen Meadows, Susan Wan et al. · International Journal of Radiation Oncology*Biology*Physics · 2008 · 144 citations

Surgical Oncology, Week Oral Regimen, Radiation Therapy +9